Are Steatosis and Steatohepatitis Triggers of Hepatic Fibrogenesis

The article displays current views on the process of fibrogenesis in patients with fatty liver disease. It is shown that steatosis and steatohepatitis are the main triggers of the process of fibrogenesis. Modern mechanisms of hepatic fibrosis were described. The issues of reversibility of fibrosis in liver diseases, particularly in fatty liver disease, are discussed. The main directions of antifibrotic therapy are shown. Administration of essential phospholipids in patients with hepatic steatosis and steatohepatitis with signs of fibrosis is appropriate from the perspective of evidence-based medicine. Enerliv® is a new generation of hepatoprotectors, it consists of fat-free soy phospholipids with a maximum degree of purity, and the concentration of phosphatidylcholine is an average of 76 % — a parameter unattainable for most preparations of essential phospholipids present in the domestic pharmaceutical market. Diffuse liver disease include membrane-associated defects and can proceed with the development of fibrosis, so the administration of phospholipids in a preparation Enerliv® can be considered as a basic therapy for fatty liver disease.